Texas hospitals are running out of drugs, beds, ventilators and even staff
Many Texas hospitals are no longer accepting transfer patients in order to maintain space for a surge that’s expected to come. In some parts of the state, it’s already here.
Related Articles
Exclusive: In $1B+ bet on AI, biopharma heavyweights back new startup to upend drug R&D
A star-studded mix of venture capitalists and scientists, backed by more than a billion dollars, is launching an ambitious biotech that aims to reinvent drug…
UK biotech signs $1bn deal to develop liver disease drugs
Ochre Bio partnering with Germany’s Boehringer Ingelheim on treatments that will harness the organ’s capacity to regenerate
Cerevel notches Phase 3 Parkinson’s win ahead of AbbVie transaction closing
As it waits for its acquisition by AbbVie to finalize, Cerevel reported a Phase 3 win for one of its programs in Parkinson’s disease. Patients…
23andMe CEO Anne Wojcicki Plans to Take Company Private
Her intentions, revealed in a public filing, comes after the once-hot company’s valuation collapsed from a high of $6 billion.
Boehringer Ingelheim touts 10-year plan as it eyes overtaking Bayer as Germany’s largest pharma
Boehringer Ingelheim put the spotlight on a pipeline ripe with milestones over the next decade during its full-year 2023 earnings call with the press. Driven…
Regeneron enters venture investing with $500M, poaches senior partner from ARCH
Regeneron, the 35-year-old drugmaker still led by its co-founders, is getting into the venture investing arena. The New York pharma will commit $100 million per…
Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs
Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is…
Exclusive: Siduma, a biotech from Arvinas’ scientific founder, shutters due to ‘financing environment’
Siduma Therapeutics, a Yale spinout from Arvinas scientific founder Craig Crews, has closed, a spokesperson for the company confirmed to Endpoints News via email Thursday.…
Novartis wanted just one drug from MorphoSys before upping bid for whole company, document reveals
Before Novartis went all in on MorphoSys for $2.9 billion in February, the Swiss pharma giant initially wanted just one key piece from the German…
Another ADC biotech reels in big bucks as Mark Alles’ TORL nabs $158M
Mark Alles has quickly put together a megaround for his latest venture, and it’s for the most sought-after pocket of oncology R&D: antibody-drug conjugates. The…